|
Leader
|
|
|
00000nz a2200037n 45 0 |
|
001
|
|
|
WKP|Q110414397
(VIAF cluster)
(Authority/Source Record)
|
|
003
|
|
|
WKP |
|
005
|
|
|
20241221010631.0 |
|
008
|
|
|
241221nneanz||abbn n and d |
|
035
|
|
|
‡a
(WKP)Q110414397
|
|
035
|
|
|
‡a
(OCoLC)Q110414397
|
|
100
|
0 |
|
‡a
Ruth March
‡9
sq
‡9
nl
|
|
375
|
|
|
‡a
2
‡2
iso5218
|
|
400
|
0 |
|
‡a
Ruth March
‡c
British genomic scientist
‡9
en
|
|
670
|
|
|
‡a
Author's A genome-wide screen for susceptibility loci in ankylosing spondylitis
|
|
670
|
|
|
‡a
Author's Automation and validation of DNA-banking systems
|
|
670
|
|
|
‡a
Author's Challenges and opportunities of pharmacogenetics in drug development
|
|
670
|
|
|
‡a
Author's Delivering on the promise of personalized healthcare
|
|
670
|
|
|
‡a
Author's Diagnostic Utility of Exome Sequencing for Kidney Disease
|
|
670
|
|
|
‡a
Author's Exome-Based Rare-Variant Analyses in CKD
|
|
670
|
|
|
‡a
Author's Gene mapping strategies for complex disease and drug response.
|
|
670
|
|
|
‡a
Author's Impact of a five-dimensional framework on R&D productivity at AstraZeneca
|
|
670
|
|
|
‡a
Author's Interstitial lung disease in gefitinib-treated Japanese patients with non-small-cell lung cancer: genome-wide analysis of genetic data.
|
|
670
|
|
|
‡a
Author's Lessons learned from the fate of AstraZeneca's drug pipeline: a five-dimensional framework
|
|
670
|
|
|
‡a
Author's Novel technology and the development of pharmacogenetics within the pharmaceutical industry
|
|
670
|
|
|
‡a
Author's Personalized/Precision Medicine/Personalised Healthcare: the art of giving different names to the same thing?
|
|
670
|
|
|
‡a
Author's Rosuvastatin pharmacokinetics and pharmacogenetics in white and Asian subjects residing in the same environment
|
|
670
|
|
|
‡a
Author's Selecting cases from nuclear families for case-control association analysis
|
|
670
|
|
|
‡a
Author's Serious carbamazepine-induced hypersensitivity reactions associated with the HSP70 gene cluster
|
|
670
|
|
|
‡a
wikidata site links
‡u
https://en.wikipedia.org/wiki/Ruth_March
|
|
919
|
|
|
‡a
genemappingstrategiesforcomplexdiseaseanddrugresponse
‡A
Gene mapping strategies for complex disease and drug response.
‡9
1
|
|
919
|
|
|
‡a
interstitiallungdiseaseingefitinibtreatedjapanesepatientswithnonsmallcelllungcancergenomewideanalysisofgeneticdata
‡A
Interstitial lung disease in gefitinib-treated Japanese patients with non-small-cell lung cancer: genome-wide analysis of genetic data.
‡9
1
|
|
919
|
|
|
‡a
lessonslearnedfromthefateofastrazenecasdrugpipelinea5dimensionalframework
‡A
Lessons learned from the fate of AstraZeneca's drug pipeline: a five-dimensional framework
‡9
1
|
|
919
|
|
|
‡a
noveltechnologyandthedevelopmentofpharmacogeneticswithinthepharmaceuticalindustry
‡A
Novel technology and the development of pharmacogenetics within the pharmaceutical industry
‡9
1
|
|
919
|
|
|
‡a
personalizedprecisionmedicinepersonalisedhealthcaretheartofgivingdifferentnamestothesamething
‡A
Personalized/Precision Medicine/Personalised Healthcare: the art of giving different names to the same thing?
‡9
1
|
|
919
|
|
|
‡a
rosuvastatinpharmacokineticsandpharmacogeneticsinwhiteandasiansubjectsresidinginthesameenvironment
‡A
Rosuvastatin pharmacokinetics and pharmacogenetics in white and Asian subjects residing in the same environment
‡9
1
|
|
919
|
|
|
‡a
selectingcasesfromnuclearfamiliesforcasecontrolassociationanalysis
‡A
Selecting cases from nuclear families for case-control association analysis
‡9
1
|
|
919
|
|
|
‡a
seriouscarbamazepineinducedhypersensitivityreactionsassociatedwiththehsp70genecluster
‡A
Serious carbamazepine-induced hypersensitivity reactions associated with the HSP70 gene cluster
‡9
1
|
|
919
|
|
|
‡a
exomebasedrarevariantanalysesinckd
‡A
Exome-Based Rare-Variant Analyses in CKD
‡9
1
|
|
919
|
|
|
‡a
diagnosticutilityofexomesequencingforkidneydisease
‡A
Diagnostic Utility of Exome Sequencing for Kidney Disease
‡9
1
|
|
919
|
|
|
‡a
deliveringonthepromiseofpersonalizedhealthcare
‡A
Delivering on the promise of personalized healthcare
‡9
1
|
|
919
|
|
|
‡a
challengesandopportunitiesofpharmacogeneticsindrugdevelopment
‡A
Challenges and opportunities of pharmacogenetics in drug development
‡9
1
|
|
919
|
|
|
‡a
automationandvalidationofdnabankingsystems
‡A
Automation and validation of DNA-banking systems
‡9
1
|
|
919
|
|
|
‡a
genomewidescreenforsusceptibilitylociinankylosingspondylitis
‡A
A genome-wide screen for susceptibility loci in ankylosing spondylitis
‡9
1
|
|
919
|
|
|
‡a
impactofa5dimensionalframeworkonr&dproductivityatastrazeneca
‡A
Impact of a five-dimensional framework on R&D productivity at AstraZeneca
‡9
1
|
|
946
|
|
|
‡a
a
‡9
1
|
|
996
|
|
|
‡2
LC|no 90011529
|
|
996
|
|
|
‡2
ISNI|0000000033938426
|
|
996
|
|
|
‡2
LC|n 98108048
|
|
996
|
|
|
‡2
LC|n 91061838
|
|
996
|
|
|
‡2
RERO|A022894553
|
|
997
|
|
|
‡a
0 0 lived 0 0
‡9
1
|
